<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525408</url>
  </required_header>
  <id_info>
    <org_study_id>CR-60/1260</org_study_id>
    <nct_id>NCT00525408</nct_id>
  </id_info>
  <brief_title>A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer</brief_title>
  <acronym>HRPC</acronym>
  <official_title>Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Pharnmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Pharnmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposed the comparison the overall survival, hematological toxicity, pain
      reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from
      different parts of India.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate Cancer is a common health issue facing men worldwide in most of the patients cancer
      will shrink with hormonal therapy. In some cases cancer returns or continues to grow despite
      very low levels of circulating male hormones, which is called Androgen-Independent Prostate
      Cancer (AIPC) or Hormone Refractory Prostate Cancer (HRPC). Mycobacterium w is known to share
      multiple antigen including PSA. It administration is associated with antigen specific
      generation of cell mediated immunity. Docetaxel is found to useful in management of
      metastatic hormone refractory prostate cancer, which is associated with improved survival,
      tumor progression free survival with reduction in pain, serum PSA and improvement in quality
      of life. Cyclophosphamide 300mg/sq.m will be used to eliminate T-regulatory cell responsible
      immuno suppression. The vaccine Mycobacterium w will be administered on a day following
      cyclophosphamide. For better initiation of immune responses Docetaxel will be given seven
      days following first dose of Mycobacterium w.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim Analysis report indicates trial futility
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Survival time</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hematological toxicity, PSA levels, Quality of Life</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Hormone Refractory Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel+Mw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mycobacterium w.</intervention_name>
    <description>Immunomodulator</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Chemotherapeutic agent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate with clinical
             or radiologic evidence of metastatic disease.

          -  Disease progression during antiandrogen therapy, having surgical or medical castration
             status.

          -  Karnofsky Performance Status 50-100

          -  Normal cardiac function

          -  Life expectancy at least 24 weeks.

          -  Laboratory criteria for eligibility will include

          -  A neutrophil count of at least 1500 per cubic millimeter

          -  A hemoglobin level of at least 9 gm%

          -  A platelet count of at least 1000,000 per cubic millimeter.

          -  A total bilirubin not grater than 1.5 times the upper limit of the normal range for
             each institution.

          -  Serum creatinine levels not more than 1.5 times the upper limit of the normal range

          -  Written informed consent

        Exclusion Criteria:

          -  Prior treatment with cytotoxic agents or radioisotopes

          -  Estrogen use for at least three months

          -  History of another cancer within the preceding five years (except basal or
             squamous-cell skin cancer)

          -  Brain or leptomeningeal metastases

          -  Symptomatic peripheral neuropathy of grade 2 or higher

          -  Uncontrolled intercurrent illness that would limit compliance with study requirements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudhir Rawal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rajiv Gandhi Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arup Kumar Mandal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Post Graduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Devakar Dalela, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chatrapati Sahuji Mahraj Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N K Mohanty, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Safdarjang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jayesh Dhabalia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SEth G S Medical College &amp; KEM Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arun Chawla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasturba Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sujata Patwardhan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LTMMC &amp; LTMGH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P G Jayaprakash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RCC, Trivandrum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amil Lal Bhat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.P. Medical College &amp; A.G. Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raju T Chacko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian Medical College, Vellore, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sushil Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Choithram Hospital &amp; Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Mammen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian Medical College, Ludhiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K C Lakshmaiah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kidwai Memorial Istitute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajeev Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Patel Hospital Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>V.M. Medical College &amp; Safdarjang Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute &amp; Research Center</name>
      <address>
        <city>Rohini</city>
        <state>Delhi</state>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidwai Memorial Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Hospital,</name>
      <address>
        <city>Manipal</city>
        <state>Karnataka</state>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Centre</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choithram Hospital &amp; Research Centre</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seth G.S. Medical College &amp; KEM Hospital</name>
      <address>
        <city>Parel</city>
        <state>Mumbai</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lokmanya Tilak Municipal Medical College &amp; General Hospital</name>
      <address>
        <city>Sion</city>
        <state>Mumbai</state>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patel Hospital Pvt. Ltd.</name>
      <address>
        <city>Jalandhar</city>
        <state>Punjab</state>
        <zip>144001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College, Ludhiana</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.P. Medical College &amp; A. G. of Hospitals</name>
      <address>
        <city>Bikaner</city>
        <state>Rajashthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatrapati Sahuji Mahraj Medical University</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>March 9, 2012</last_update_submitted>
  <last_update_submitted_qc>March 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HRPC</keyword>
  <keyword>Metastatic Hormone Refractory Prostate Cancer</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Mycobacterium w</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

